# Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

> **NCT00053508** · PHASE2 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 274 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** ACAM1000
- **BIOLOGICAL:** vaccinia virus (calf lymph) smallpox vaccine: Dryvax

## Key facts

- **NCT ID:** NCT00053508
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-09
- **Primary completion:** 2003-03
- **Final completion:** 2003-09
- **Target enrollment:** 274 (ACTUAL)
- **Why stopped:** CDC's decision to down-select vaccine development to single candidate, ACAM2000
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053508, "Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00053508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*